JNM CE/SAM (March 2022): Principles of Tracer Kinetic Analysis in Oncology, Part I: Principles and Overview of Methodology

MOC Part II SAM Modules

JNM CE/SAM (March 2022): Principles of Tracer Kinetic Analysis in Oncology, Part I: Principles and Overview of Methodology

JNM, October 2021, Volume 62, Number 10
Release Date: October1, 2021
Expiration Date: October 31, 2024

SNMMI Members: Free
Non-Members: $69.00

Continuing Education Credit Information

The American Board of Nuclear Medicine has reviewed and approved this Journal SAM activity submitted by the SNMMI. This activity fulfills the requirements of the ABNM Maintenance of Certification program for self-assessment. 2.0 SAMs have been awarded for this activity.

AMA-PRA (Physician)

The Society for Nuclear Medicine and Medical Imaging, Inc. (SNMMI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. SNMMI designates this enduring material for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Austin R. Pantel1, Varsha Viswanath1, Mark Muzi2, Robert K. Doot1, and David A. Mankoff1
1Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania; and 2Department of Radiology, University of Washington, Seattle, Washington

This work was supported by KL2 TR001879, R01 CA211337, R01 CA113941, R33 CA225310, Komen SAC130060, R50 CA211270, and K01 DA040023. Dr. Pantel is a consultant or advisor for Progenics and Blue Earth Diagnostics and is a meeting participant or lecturer for Blue Earth Diagnostics. Dr. Mankoff is on the scientific advisory boards of GE Healthcare, Philips Healthcare, Reflexion, and ImaginAb and is the owner of Trevarx; his wife is the chief executive officer of Trevarx. In accordance with ACCME Revised Standards for Commercial Support and SNMMI Conflict-of-Interest Policy, the authors have indicated no other relevant relationships that could be perceived as a real or apparent conflict of interest. Disclosure of a relationship is not intended to suggest or to condone bias but is made to provide participants with information that might be of potential importance to their evaluation of the activity.

Target Audience
This article contains information of value to practicing nuclear medicine physicians and technologists with an interest in quantitative cancer molecular imaging.

On successful completion of this activity, participants should be able to…
1. Describe principles of PET tracer kinetic analysis for oncologic applications.
2. List methods used for PET kinetic analysis for oncology.
3. Discuss application of kinetic modeling for cancer-specific diagnostic needs.

Contact Information

For questions please contact Lisa Dickinson, Associate Director of Education at ldickinson@snmmi.org or 703-652-6783.